Drug Profile
ABY 029
Alternative Names: ABY-029 trifluoroacetate salt; fluorescently-labeled Anti-EGFR affibody molecule; IRDye 800CW maleimide-labeled affibody peptideLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Affibody; Dartmouth College; LI-COR Biosciences
- Developer Dartmouth College
- Class Imaging agents; Peptide diagnostics
- Mechanism of Action Diagnostic imaging enhancers; Epidermal growth factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glioma
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for phase-0 development in Glioma(Diagnosis) in USA (IV, Injection)
- 20 Sep 2017 Dartmouth-Hitchcock Medical Center plans a phase I trial for Head and neck cancer in USA (NCT03282461)
- 23 May 2017 Dartmouth College plans a phase 0 trial for Soft-tissue Sarcoma (Diagnosis) in USA (NCT03154411)